All In Biotech

Drug Trial Radar · NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,578

Actual

Start

Jun 9, 2003

Primary completion

Sep 30, 2020

Study completion Sep 30, 2020

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Aug 1, 2002

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

IMPAACT P1026s is a Phase IV prospective clinical study to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study also evaluated the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs were evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.

Conditions

  • HIV Infections

Interventions

  • atazanavir/cobicistatDrug

    atazanavir/cobicistat 300/150 mg q.d.

  • darunavir/ritonavir dosage #1Drug

    darunavir/ritonavir twice daily 600/100 mg b.i.d.

  • darunavir/ritonavir dosage #2Drug

    darunavir/ritonavir twice daily 800/100 mg b.i.d.

  • darunavir/ritonavir dosage #3Drug

    darunavir/ritonavir twice daily 900/100 mg b.i.d.

  • elvitegravir/cobicistatDrug

    elvitegravir/cobicistat 150/150 mg q.d.

  • dolutegravirDrug

    dolutegravir 50 mg q.d.

  • tenofovir alafenamide fumarate (TAF)Drug

    TAF 25 mg q.d. without cobicistat or ritonavir boosting

  • TAF w/cobicistatDrug

    TAF 10 mg q.d. with cobicistat

  • TAF w/cobicistat or ritonavirDrug

    TAF 25 mg q.d. with cobicistat or ritonavir boosting

  • efavirenzDrug

    efavirenz 600 mg q.d.

  • darunavir/cobicistatDrug

    darunavir/cobicistat 800/150 mg q.d.

  • lopinavir/ritonavir dosage #1Drug

    lopinavir/ritonavir 800/200mg b.i.d.

  • atazanavir/ritonavir/tenofovir dosage #1Drug

    atazanavir/ritonavir/tenofovir 300/100/300mg q.d.

  • rifampicinDrug

    rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

  • ethambutolDrug

    ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.

  • isoniazidDrug

    isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

  • pyrazinamideDrug

    pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.

  • kanamycinDrug

    kanamycin (2nd line TB drug)

  • amikacinDrug

    amikacin (2nd line TB drug)

  • capreomycinDrug

    capreomycin (2nd line TB drug)

  • moxifloxacinDrug

    moxifloxacin (2nd line TB drug)

  • levoflaxacinDrug

    levofloxacin (2nd line TB drug)

  • ofloxacinDrug

    ofloxacin (2nd line TB drug)

  • ethionamide/prothionamideDrug

    ethionamide/prothionamide (2nd line TB drug)

  • terizidone/cycloserineDrug

    terizidone/cycloserine (2nd line TB drug)

  • para-aminosalicylic acid (PAS)Drug

    para-aminosalicylic acid (PAS) (2nd line TB drug)

  • high dose INHDrug

    high dose INH (2nd line TB drug)

  • bedaquilineDrug

    bedaquiline (2nd line TB drug)

  • clofazamineDrug

    clofazamine (2nd TB drug)

  • delamanidDrug

    delamanid (2nd line TB drug)

  • linezolidDrug

    linezolid (2nd line TB drug)

  • pretomanidDrug

    pretomanid (2nd line TB drug)

  • ethinyl estradiolDrug

    oral contraceptives formulated with 30-35 μg ethinyl estradiol

  • etonogestrel implantDrug

    etonogestrel implant contraceptive

  • nevirapineDrug

    nevirapine 200 mg twice a day

  • amprenavirDrug

    amprenavir 1200mg twice a day

  • abacavirDrug

    abacavir 300mg twice a day

  • lopinavir/ritonavir dosage #2Drug

    lopinavir/ritonavir (Kaletra) 400/100mg twice a day

  • indinavir/ritonavir dosage #1Drug

    indinavir/ritonavir 800/100mg twice a day

  • fosamprenavir/ritonavirDrug

    fosamprenavir/ritonavir 700/100 mg twice a day

  • lopinavir/ritonavir dosage #3Drug

    lopinavir/ritonavir (Kaletra) 533/133 mg twice a day

  • atazanavir/ritonavir dosage #1Drug

    atazanavir/ritonavir 300/100 mg once a day

  • didanosine delayed release (Videx® EC)Drug

    didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg

  • emtricitabineDrug

    emtricitabine 200 mg once a day

  • tenofovirDrug

    tenofovir 300 mg once a day

  • nelfinavir dosage #1Drug

    nelfinavir \[625 mg tablets\] 1250 mg twice a day

  • tipranavir/ritonavirDrug

    tipranavir/ritonavir 500/200 mg twice a day

  • lopinavir/ritonavir dosage #4Drug

    lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day

  • raltegravirDrug

    raltegravir 400 mg twice a day

  • etravirineDrug

    etravirine 200 mg twice a day

  • maravirocDrug

    maraviroc 150 mg or 300 mg twice a day

  • atazanavir/ritonavir dosage #2Drug

    atazanavir/ritonavir 400/100mg once a day

  • tenofovir/atazanavir/ritonavir dosage #2Drug

    tenofovir/atazanavir/ritonavir 300/400/100 mg once a day

  • nelfinavir dosage #2Drug

    nelfinavir \[625 mg tablets\] 1875 mg twice a day

  • indinavir/ritonavir dosage #2Drug

    indinavir/ritonavir 400/100 mg twice a day

  • rilpivirineDrug

    rilpivirine (25 mg q.d.)

  • darunavir/ritonavir dosage #4Drug

    darunavir/ritonavir once daily 800/100 mg q.d.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
  2. PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
  3. PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
  4. PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
  5. PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
  6. PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
  7. PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
  8. PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
  9. PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
  10. PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
  11. PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
  12. PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
  13. PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
  14. PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
  15. Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
  16. Number of Women Who Met PK Target of Maximum Concentration (Cmax) for First Line TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
  17. Plasma Concentration for ContraceptivesTime frame: Measured at 6-7 weeks after contraceptive initiation postpartum
  18. Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive ArmsTime frame: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.
  19. Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive ArmsTime frame: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

Locations

62 sites in 8 countries. Site status is shown where the registry gives one.

  • UAB Pediatric Infectious Diseases CRS

    Birmingham, Alabama

  • University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program

    La Jolla, California

  • Miller Children's Hosp. Long Beach CA NICHD CRS

    Long Beach, California

  • Usc La Nichd Crs

    Los Angeles, California

  • David Geffen School of Medicine at UCLA NICHD CRS

    Los Angeles, California

  • Univ. of California San Francisco NICHD CRS

    San Francisco, California

  • Harbor UCLA Medical Ctr. NICHD CRS

    Torrance, California

  • Univ. of Colorado Denver NICHD CRS

    Aurora, Colorado

  • Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease

    New Haven, Connecticut

  • Washington Hosp. Ctr. NICHD CRS

    Washington D.C., District of Columbia

  • Univ. of Florida Jacksonville NICHD CRS

    Jacksonville, Florida

  • Pediatric Perinatal HIV Clinical Trials Unit CRS

    Miami, Florida

  • USF - Tampa NICHD CRS

    Tampa, Florida

  • Emory University School of Medicine NICHD CRS

    Atlanta, Georgia

  • Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases

    Augusta, Georgia

  • Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program

    Chicago, Illinois

  • Rush Univ. Cook County Hosp. Chicago NICHD CRS

    Chicago, Illinois

  • Univ. of Illinois College of Medicine at Chicago, Dept. of Peds.

    Chicago, Illinois

  • Lurie Children's Hospital of Chicago (LCH) CRS

    Chicago, Illinois

  • Tulane Univ. New Orleans NICHD CRS

    New Orleans, Louisiana

  • Univ. of Maryland Baltimore NICHD CRS

    Baltimore, Maryland

  • Johns Hopkins Univ. Baltimore NICHD CRS

    Baltimore, Maryland

  • Children's Hosp. of Boston NICHD CRS

    Boston, Massachusetts

  • Boston Medical Center Ped. HIV Program NICHD CRS

    Boston, Massachusetts

  • Baystate Health, Baystate Med. Ctr.

    Springfield, Massachusetts

  • WNE Maternal Pediatric Adolescent AIDS CRS

    Worcester, Massachusetts

  • Children's Hospital of Michigan NICHD CRS

    Detroit, Michigan

  • Rutgers - New Jersey Medical School CRS

    Newark, New Jersey

  • Nyu Ny Nichd Crs

    New York, New York

  • Metropolitan Hosp. NICHD CRS

    New York, New York

  • Columbia IMPAACT CRS

    New York, New York

  • SUNY Stony Brook NICHD CRS

    Stony Brook, New York

  • Bronx-Lebanon Hospital Center NICHD CRS

    The Bronx, New York

  • Jacobi Med. Ctr. Bronx NICHD CRS

    The Bronx, New York

  • DUMC Ped. CRS

    Durham, North Carolina

  • Philadelphia IMPAACT Unit CRS

    Philadelphia, Pennsylvania

  • Regional Med. Ctr. at Memphis

    Memphis, Tennessee

  • St. Jude Children's Research Hospital CRS

    Memphis, Tennessee

  • Seattle Children's Research Institute CRS

    Seattle, Washington

  • Hosp. General de Agudos Buenos Aires Argentina NICHD CRS

    Ciudad de Buenos Aires, Buenos Aires, Argentina

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.